Two Sigma Securities’s Iovance Biotherapeutics IOVA Stock Holding History

Two Sigma Securities’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$86.2K	Buy	24,565 +10,525	+75%	+$33.7K	0.01%	1195
2025 Q4	$38.3K	Buy	+14,040	New	+$32.5K	0.01%	1108
2025 Q3	–	Sell	-45,858	Closed	-$78.9K	–	1700
2025 Q2	$78.9K	Buy	+45,858	New	+$114K	0.01%	1070
2024 Q3	–	Sell	-11,483	Closed	-$92.1K	–	3226
2024 Q2	$92.1K	Buy	+11,483	New	+$123K	﹤0.01%	2497
2017 Q3	–	Sell	-13,763	Closed	-$101K	–	1061
2017 Q2	$101K	Buy	+13,763	New	+$87.5K	0.02%	651

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Two Sigma Securities's IOVA Position: Q1 2026 in Review

Two Sigma Securities increased its Iovance Biotherapeutics (IOVA) stake by 75% in Q1 2026, buying an estimated $33.7K and bringing the position to 24,565 shares worth $86.2K. The position accounts for 0.01% of the portfolio, ranked #1195.

Two Sigma Securities first reported a position in IOVA in Q2 2017 and has held it in 5 quarters since. The position peaked at $101K in Q2 2017. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Two Sigma Securities held 24,565 shares of Iovance Biotherapeutics worth $86.2K as of Q1 2026.
Two Sigma Securities bought 10,525 Iovance Biotherapeutics shares in Q1 2026, an estimated $33.7K.
Iovance Biotherapeutics made up 0.01% of Two Sigma Securities's portfolio in Q1 2026, its #1195 holding.
Two Sigma Securities first reported a position in Iovance Biotherapeutics in Q2 2017 and has held it in 5 quarters since.
Two Sigma Securities's Iovance Biotherapeutics position peaked at $101K in Q2 2017.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.